SELP and systemic lupus erythematosus: Particularly, P-selectin has emerged as a therapeutic target in various diseases, including cardiovascular conditions, systemic lupus erythematosus, and sickle cell anemia (Ataga et al., 2017; Scherlinger et al., 2021; Schmitt et al., 2015).